Jean Francois Formela - 17 Aug 2021 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Reporting relationship: Director
Issuer ticker: SPRO
Reported as of: 17 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2021, 16:41:29 UTC
Prior SEC filing: 29 Jun 2021
Next SEC filing: 14 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Matthew J. Gardella, as Attorney-in-Fact for Jean Francois Formela

Key filing fact

Jean Francois Formela filed Form 4 for Spero Therapeutics, Inc. (SPRO) on 18 Aug 2021.

Key facts

This page summarizes Jean Francois Formela's Form 4 filing for Spero Therapeutics, Inc. (SPRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2021, 16:41.

Change

Previous filing in this sequence was filed on 29 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,500
Change %
Price: $0.000000
Shares after: 7,500
Date: 17 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $13.69
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date.

Footnote F2

The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.